New Delhi Apr 18 PTI The countrys largest carmaker Maruti Suzuki India MSI on Monday said it has increased prices of its entire model range with immediate effect in order to partially offset the impact of rise in input costs The company which sells a range of vehicles from Alto to S-Cross said the weighted average increase across models is 13 per cent ex showroom Delhi In a regulatory filing on April 6 the company had noted that the cost of its vehicles continues to be adversely impacted due to increase in various input costs MSI has already hiked vehicle prices by around 88 per cent from January 2021 to March 2022 owing to constant increase in input costs PTI MSS DRR

New Delhi Mar 24 PTI The countrys largest carmaker Maruti Suzuki India MSI on Thursday said it has appointed Hisashi Takeuchi as the new Managing Director and CEO with effect from April 1 2022 The companys board in its meeting held on Thursday appointed Takeuchi as the Managing Director and CEO from April 1 consequent to the completion of the term of Kenichi Ayukawa on March 31 2022 MSI said in a statement In order to facilitate a smooth transition Ayukawa will continue as a whole-time Director designated as Executive Vice Chairman till September 30 2022 and will continue to provide guidance to the auto major it added The appointments are subject to shareholder approval MSI noted Takeuchi joined Suzuki Motor Corporation SMC in 1986 With vast experience in the international operations at SMC as well as in overseas markets he has been on the Board of Maruti Suzuki since July 2019 as Joint Managing Director Commercial since April 2021 I thank the Board of Directors for placing this trust in me Maruti Suzuki is a great organisation with a rich legacy and it will be my endeavour that we keep serving more and more customers both in India and the world with exciting cars that are good for them environment and society We will also try to build our business in a manner that strengthens Atma-Nirbhar Bharat and the economic growth of India he stated Ayukawa who has been the Managing Director and CEO of the company since April 2013 termed his stint as both challenging and fulfilling India is one of the most interesting and promising automobile markets in the world and it has been both a challenging and a fulfilling stint for me Takeuchi has an excellent understanding of the Indian as well as international markets and is placed well to lead Maruti Suzuki into the future I wish him a successful journey ahead he said The automaker whose market share in about 30-lakh-strong volume domestic passenger vehicle segment has come down to 45 per cent this year from 48 per cent last year is looking to fill gaps in the various sub-segments that have emerged in the SUV space in the past few years PTI MSS DRR

New Delhi Dec 28 PTI Drug major Cipla on Tuesday said it has received emergency use authorisation EUA permission from the Drug Controller General of India DCGI to launch antiviral drug Molnupiravir in the country to treat mild-to-moderate COVID-19 The Mumbai-based firm said it plans to launch Molnupiravir under the brand name Cipmolnu This launch is yet another step in our endeavour to enable access to all treatments in COVID care We continue to be guided by the power of science to address the unmet needs of patients across the globe and bring care closer to the patients Cipla MD and Global CEO Umang Vohra said in a statement Earlier during the year Cipla entered into a non-exclusive voluntary licensing agreement with Merck Sharpe Dohme MSD to manufacture and supply Molnupiravir in India and to over 100 low and middle-income countries LMICs The regulatory approval comes on the back of a five-month collaborative trial conducted by a consortium of companies Molnupiravir is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency MHRA for the treatment of mild-to-moderate COVID-19 at high risk of developing severe disease Molnupiravir inhibits the replication of multiple RNA viruses including SARS-CoV-2 Cipla said it will soon make Cipmolnu 200mg capsules available at all leading pharmacies and COVID treatment centers across the country The company has adequate manufacturing capacities and a solid distribution mechanism in place to ensure speedy access to this effective treatment pan India it added PTI MSS DRR